首页> 美国卫生研究院文献>World Journal of Transplantation >Recent progress in pancreatic islet transplantation
【2h】

Recent progress in pancreatic islet transplantation

机译:胰岛移植的最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetes mellitus remains a major burden. More than 200 million people are affected worldwide, which represents 6% of the world’s population. Type 1 diabetes mellitus is an autoimmune disease, which induces the permanent destruction of the β-cells of the pancreatic islets of Langerhans. Although intensive insulin therapy has proven effective to delay and sometimes prevent the progression of complications such as nephropathy, neuropathy or retinopathy, it is difficult to achieve and maintain long term in most subjects. The successes achieved over the last few decades by the transplantation of whole pancreas and isolated islets suggest that diabetes can be cured by the replenishment of deficient β cells. However, islet transplantation efforts have various limitations, including the limited supply of donor pancreata, the paucity of experienced islet isolation teams, side effects of immunosuppressants and poor long term results. The purpose of this article is to review the recent progress in clinical islet transplantation for the treatment of diabetes and to describe the recent progress on pancreatic stem/progenitor cell research, which has opened up several possibilities for the development of new treatments for diabetes.
机译:糖尿病仍然是主要负担。全球有超过2亿人受到影响,占世界人口的6%。 1型糖尿病是一种自身免疫性疾病,可引起Langerhans胰岛β细胞的永久破坏。尽管强化胰岛素治疗已被证明可以有效地延迟并有时防止并发症的发展,例如肾病,神经病或视网膜病,但在大多数受试者中很难长期维持。在过去的几十年中,通过全胰腺和离体胰岛的移植取得的成功表明,可以通过补充缺乏的β细胞来治愈糖尿病。但是,胰岛移植的努力有很多局限性,包括供体胰脏的供应有限,经验丰富的胰岛分离团队的匮乏,免疫抑制剂的副作用以及长期效果不佳。本文的目的是回顾用于治疗糖尿病的临床胰岛移植的最新进展,并描述胰腺干/祖细胞研究的最新进展,这为开发新的糖尿病治疗方法提供了多种可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号